Cystic fibrosis, also known as mucoviscidosis, is a genetically inherited, chronic disease and is progressive in nature. The onset of cystic fibrosis typically occurs in early childhood or, rarely, at birth. The primary symptoms of cystic fibrosis include breathing difficulties, high salt content in the sweat, and secretion of abnormally viscous mucus. The principal indicators of cystic fibrosis in patients are pancreatic insufficiency, pancreatitis, chronic bronchitis, adolescent diabetes, male sterility, and very rarely liver cirrhosis or intestinal obstruction. The most usual forms of cystic fibrosis are those with respiratory complications, difficulties related to digestion, and anomalies in height and growth. The mortality and morbidity of a patient are dependent on the degree of bronchopulmonary involvement.

PART 01: Executive summary

Highlights

PART 02: Scope of the report

Market overview

Top-vendor offerings

PART 03: Market research methodology

Research methodology

Economic indicators

PART 04: Introduction

Key market highlights

PART 05: Disease overview

Understanding the disease

Pathophysiology

Diagnosis

Manifestations of cystic fibrosis

PART 06: Pipeline analysis

PART 07: Market landscape

Market overview

Market size and forecast

Five forces analysis

PART 08: Market segmentation by drug class

CFTR modulators

Mucolytics

PERT

Anti-infectives

Bronchodilators

PART 09: Market segmentation by molecule type

Small molecules

Biologics

PART 10: Geographical segmentation

Global cystic fibrosis therapeutics market by

geography

Cystic fibrosis therapeutics market in Americas

Cystic fibrosis therapeutics market in EMEA

Cystic fibrosis therapeutics market in APAC

PART 11: Key leading countries

The US

The UK

France

Canada

Italy

PART 12: Market drivers

Special regulatory designations for drugs

Increased uptake of CFTR modulators

Improvement in diagnostic technologies

PART 13: Impact of drivers

PART 14: Market challenges

Discontinuation of drugs from development

Difficulty in developing drugs due to rarity of disease

PART 15: Impact of drivers and challenges

PART 16: Market trends

Co-pay and assistance programs by vendors

Strategic collaborations

Advances in technology for drug development and

delivery

PART 17: Vendor landscape

Competitive scenario

Other prominent vendors

PART 18: Key vendor analysis

Vertex Pharmaceuticals

F. Hoffmann-La Roche

AbbVie

Gilead Sciences

Novartis

PART 19: Appendix

List of abbreviations

PART 20: Explore Technavio